91 related articles for article (PubMed ID: 31076447)
1. Spectrum of
Rotunno G; Mannarelli C; Brogi G; Pacilli A; Gesullo F; Mannelli F; Fiaccabrino S; Sordi B; Paoli C; Marone I; Rumi E; Manfredini R; Barosi G; Cazzola M; Vannucchi AM; Guglielmelli P
Blood; 2019 Jun; 133(26):2802-2808. PubMed ID: 31076447
[No Abstract] [Full Text] [Related]
2. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
4. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.
Tefferi A; Lasho TL; Finke C; Gangat N; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 Mar; 32(3):837-839. PubMed ID: 29089644
[No Abstract] [Full Text] [Related]
6. Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis.
Tefferi A; Lasho TL; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Br J Haematol; 2018 Nov; 183(4):678-681. PubMed ID: 29171022
[No Abstract] [Full Text] [Related]
7. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
Tefferi A; Guglielmelli P; Lasho TL; Rotunno G; Finke C; Mannarelli C; Belachew AA; Pancrazzi A; Wassie EA; Ketterling RP; Hanson CA; Pardanani A; Vannucchi AM
Leukemia; 2014 Jul; 28(7):1494-500. PubMed ID: 24496303
[TBL] [Abstract][Full Text] [Related]
8. Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis.
Scheps K; Meyer C; Bestach Y; Enrico A; Bengió R; Rodríguez-Zubieta M; Rivas M; De Brasi C; Larripa I
Int J Lab Hematol; 2018 Aug; 40(4):e82-e86. PubMed ID: 29761621
[No Abstract] [Full Text] [Related]
9. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
Guo Y; Zhou Y; Yamatomo S; Yang H; Zhang P; Chen S; Nimer SD; Zhao ZJ; Xu M; Bai J; Yang FC
Leukemia; 2019 May; 33(5):1287-1291. PubMed ID: 30651633
[No Abstract] [Full Text] [Related]
10. ASXL1 mutations in primary and secondary myelofibrosis.
Ricci C; Spinelli O; Salmoiraghi S; Finazzi G; Carobbio A; Rambaldi A
Br J Haematol; 2012 Feb; 156(3):404-7. PubMed ID: 21923651
[No Abstract] [Full Text] [Related]
11. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.
Wang YH; Lin CC; Lee SH; Tsai CH; Wu SJ; Hou HA; Huang TC; Kuo YY; Yao M; Chang K; Lin CW; Lin YC; Tien FM; Chou WC; Tang JL; Tien HF
Blood Cancer J; 2020 Oct; 10(10):99. PubMed ID: 33046688
[No Abstract] [Full Text] [Related]
12. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
[TBL] [Abstract][Full Text] [Related]
13. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Guglielmelli P; Lasho TL; Rotunno G; Score J; Mannarelli C; Pancrazzi A; Biamonte F; Pardanani A; Zoi K; Reiter A; Duncombe A; Fanelli T; Pietra D; Rumi E; Finke C; Gangat N; Ketterling RP; Knudson RA; Hanson CA; Bosi A; Pereira A; Manfredini R; Cervantes F; Barosi G; Cazzola M; Cross NC; Vannucchi AM; Tefferi A
Leukemia; 2014 Sep; 28(9):1804-10. PubMed ID: 24549259
[TBL] [Abstract][Full Text] [Related]
14. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.
Ferrer-Marín F; Bellosillo B; Martínez-Avilés L; Soler G; Carbonell P; Luengo-Gil G; Caparrós E; Torregrosa JM; Besses C; Vicente V
J Hematol Oncol; 2013 Sep; 6():68. PubMed ID: 24011025
[TBL] [Abstract][Full Text] [Related]
15. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.
Guglielmelli P; Rotunno G; Fanelli T; Pacilli A; Brogi G; Calabresi L; Pancrazzi A; Vannucchi AM
Blood Cancer J; 2015 Oct; 5(10):e360. PubMed ID: 26473532
[No Abstract] [Full Text] [Related]
16. Clinical and molecular genetic characterization of myelofibrosis.
Hobbs GS; Rampal RK
Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
[TBL] [Abstract][Full Text] [Related]
17. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun JM; Song S; Koh Y; Yoon SS; Kim D
Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
[TBL] [Abstract][Full Text] [Related]
18. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
19. Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.
Yan X; Xu Z; Zhang P; Sun Q; Jia Y; Qin T; Qu S; Pan L; Li Z; Liu J; Song Z; Gao Q; Jiao M; Gong J; Wang H; Li B; Xiao Z
Blood Cancer J; 2023 Apr; 13(1):56. PubMed ID: 37080954
[No Abstract] [Full Text] [Related]
20. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
